2024 World Conference on Lung Cancer (WCLC) - Posters-P2.11A.13 Cytokine Release Syndrome from Dual Immune Checkpoint Blockade in Non-Small Cell Lung Cancer: FAERS Analysis

P2.11A.13 Cytokine Release Syndrome from Dual Immune Checkpoint Blockade in Non-Small Cell Lung Cancer: FAERS Analysis

Pdf Summary

This study conducted by researchers from the Roswell Park Comprehensive Cancer Center and the Mayo Clinic examined the occurrence of cytokine release syndrome (CRS) in patients with non-small cell lung cancer (NSCLC) treated with dual immune checkpoint blockade (ICB) therapy targeting PD-1/PD-L1 and CTLA-4. Through an analysis of the FDA's Adverse Events Reporting System (FAERS) database and a systematic review, the researchers aimed to understand the clinical characteristics of CRS in this context.<br /><br />The study identified 81 cases of CRS in NSCLC patients treated with ICB, of which 58 involved dual ICB therapy. The majority of these cases were reported from Asia. The results emphasize a significant occurrence of CRS with dual ICB compared to monotherapy. The median age of patients with CRS was around 68-69 years, with a slightly higher incidence among males. Most patients required high-dose glucocorticoid treatment to manage CRS, and early detection and treatment strategies were deemed necessary.<br /><br />The analysis highlighted that CRS is a notable adverse event in NSCLC patients undergoing dual ICB, especially in the Asian population, suggesting the need for further research into specific risk factors and the role of immune homeostasis. The study called for enhanced strategies for early detection and management of CRS, emphasizing the requirement of high-dose steroids and additional immunosuppressants for severe cases.<br /><br />The systematic review component confirmed these findings by focusing on 10 detailed NSCLC cases with CRS linked to dual ICB, further validating the data from the FAERS analysis. These insights could drive future clinical protocols to improve patient outcomes and mitigate CRS risks during ICB treatments.

Asset Subtitle

Yu Fujiwara

Meta Tag

Speaker Yu Fujiwara

Topic Metastatic NSCLC – Immunotherapy

Keywords

cytokine release syndrome

non-small cell lung cancer

immune checkpoint blockade

PD-1/PD-L1

CTLA-4

dual ICB therapy

FAERS database

glucocorticoid treatment

Asian population

immune homeostasis